2023
TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease
Zekavat S, Viana-Huete V, Matesanz N, Jorshery S, Zuriaga M, Uddin M, Trinder M, Paruchuri K, Zorita V, Ferrer-Pérez A, Amorós-Pérez M, Kunderfranco P, Carriero R, Greco C, Aroca-Crevillen A, Hidalgo A, Damrauer S, Ballantyne C, Niroula A, Gibson C, Pirruccello J, Griffin G, Ebert B, Libby P, Fuster V, Zhao H, Ghassemi M, Natarajan P, Bick A, Fuster J, Klarin D. TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease. Nature Cardiovascular Research 2023, 2: 144-158. PMID: 36949957, PMCID: PMC10026701, DOI: 10.1038/s44161-022-00206-6.Peer-Reviewed Original ResearchPeripheral artery diseaseIncident peripheral artery diseaseArtery diseaseAtherosclerotic diseaseChimeric miceIncident atherosclerotic diseaseCoronary artery diseaseAortic plaque sizeAccumulation of macrophagesMass General Brigham BiobankEntire arterial systemWhole-exome sequencingDNA damage repair genesCause mortalityCoronary arteryHematologic malignanciesPlaque macrophagesClinical dataTransplantation strategiesArterial systemPlaque sizeAtherosclerosisClonal hematopoiesisDiseaseIndeterminate potential
2022
Association of Kidney Comorbidities and Acute Kidney Failure With Unfavorable Outcomes After COVID-19 in Individuals With the Sickle Cell Trait
Verma A, Huffman JE, Gao L, Minnier J, Wu WC, Cho K, Ho YL, Gorman BR, Pyarajan S, Rajeevan N, Garcon H, Joseph J, McGeary JE, Suzuki A, Reaven PD, Wan ES, Lynch JA, Petersen JM, Meigs JB, Freiberg MS, Gatsby E, Lynch KE, Zekavat SM, Natarajan P, Dalal S, Jhala DN, Arjomandi M, Bonomo RA, Thompson TK, Pathak GA, Zhou JJ, Donskey CJ, Madduri RK, Wells QS, Gelernter J, Huang RDL, Polimanti R, Chang KM, Liao KP, Tsao PS, Sun YV, Wilson PWF, O’Donnell C, Hung AM, Gaziano JM, Hauger RL, Iyengar SK, Luoh SW, Muralidhar S, Beckham J, Moser J, Thomann L, Garcon H, Kosik N, Damrauer S, Assimes T, Roussos P, Striker R, Tuteja S, DuVall S, Lynch K, Gatsby E, Ramoni R, Breeling J, Huang G, Whitbourne S, Brewer J, Aslan M, Connor T, Argyres D, Stephens B, Brophy M, Humphries D, Selva L, Do N, Shayan S, Churby L, Hauser E, Zhao H, Wilson P, McArdle R, Dellitalia L, Mattocks K, Harley J, Whittle J, Jacono F, Wells J, Gutierrez S, Gibson G, Hammer K, Kaminsky L, Villareal G, Kinlay S, Xu J, Hamner M, Mathew R, Bhushan S, Iruvanti P, Godschalk M, Ballas Z, Ivins D, Mastorides S, Moorman J, Gappy S, Klein J, Ratcliffe N, Florez H, Okusaga O, Murdoch M, Sriram P, Yeh S, Tandon N, Jhala D, Aguayo S, Cohen D, Sharma S, Liangpunsakul S, Oursler K, Whooley M, Ahuja S, Constans J, Meyer P, Greco J, Rauchman M, Servatius R, Gaddy M, Wallbom A, Morgan T, Stapley T, Sherman S, Ross G, Tsao P, Strollo P, Boyko E, Meyer L, Gupta S, Huq M, Fayad J, Hung A, Lichy J, Hurley R, Robey B. Association of Kidney Comorbidities and Acute Kidney Failure With Unfavorable Outcomes After COVID-19 in Individuals With the Sickle Cell Trait. JAMA Internal Medicine 2022, 182: 796-804. PMID: 35759254, PMCID: PMC9237798, DOI: 10.1001/jamainternmed.2022.2141.Peer-Reviewed Original ResearchConceptsAcute kidney failureSickle cell traitAssociation of SCTCOVID-19 outcomesCOVID-19 mortalityKidney diseaseKidney failureCell traitMillion Veteran ProgramCOVID-19Chronic kidney diseaseDiabetic kidney diseaseHypertensive kidney diseaseElectronic health recordsIndex dateAfrican ancestryPulmonary embolismClinical outcomesCerebrovascular diseaseMean ageUnfavorable outcomeClinical dataDiseases codesKidney morbidityMAIN OUTCOME